La Société Européenne d’Athérosclérose, en collaboration avec FH Europe, organise 7eme Symposium PED-FH le 25 mai 2024 à Lyon, en amont du 92e Congrès de l’EAS.
Les sujets abordés seront :
– présentation, génétique et prise en charge des dyslipidémies rares chez l’enfant
– initiation et cibles du traitement LDL-C chez les enfants avec hypercholestérolémie familiale (FH)
– optimiser l’adhésion et le suivi d’un traitement hypolipidémiant chez les adolescents avec FH.
Plus d’informations et inscription gratuite via ce lien.
Programme détaillé :
| 10.00-10.05 | Welcome – Steve Humphries (UK) and Noel Peretti (France) |
| 10.05-11.20 | Rare dyslipidemias in children: Clinical presentation and early diagnosis Chairs: Noel Peretti (France) and Mafalda Bourbon (Portugal) |
| 10.05-10.20 | Familial Chylomicron Syndrome (FCS) – Sybile Charriere (France) |
| 10.20-10.35 | Living with Familial Chylomicronaemia Syndrome – the patient experience – Jill Prawer (FH Europe Foundation) |
| 10.35-10.50 | Lysosome Acid Lipase Deficiency (LAL-D) – Stella Reichmannova (Czech Republic) |
| 10.50-11.05 | Sitosterolaemia – Diagnosis, Genetics and Management – Emil Asprusten (Norway) |
| 11.05-11.25 | 2x Clinical Scenarios – Led by Uma Ramaswami (UK) |
| 11.25-11.50 | Coffee break |
| 11.50-13.00 | Is it time to lower targets for initiation and on treatment LDL-C? Chairs: Kirsten Holven (Norway) and Marianne Becker (Luxembourg) |
| 11.50-12.10 | The update of the EAS Paediatric FH Guidelines – Albert Wiegman (The Netherlands) |
| 12.10-12.25 | Treatment goals in FH – time to consider LDL-C burden – Martin Bogsrud (Norway) |
| 12.25-12.40 | Do we need different LDL-C thresholds/targets in different countries? – Kanika Dharmayat (UK) |
| 12.40-12.55 | The IAS initiative on Neonatal screening for FH – Raul Santos (Brazil) |
| 13.00-14.00 | Lunch |
| 14.00-15.50 | How to maximise compliance and adherence to treatment in adolescents with FH Universal Screening in childhood Chairs: Magdalena Daccord (FH Europe) and Jeanine Roeters van Lennep (The Netherlands) |
| 14.00-14.20 | What psychological factors influence adherence to treatment in childhood and adolescence? – Fiona Kinnear (UK) |
| 14.20-14.35 | Maximising adherence: The Australian experience – Gerald Watts (Australia) |
| 14.35-14.50 | Predicting non-adherence in patients with FH – Annette Galema-Boers (Netherlands) |
| 14.50-15.10 | What do patients find that encourages or discourages adherence to medication and lifestyle advice – Elsie Evans (UK) & Danique van den Bogert (The Netherlands) |
| 15.10-15.25 | What can we learn from the experience with Type 1 Diabetes – Carine de Beaufort (Luxembourg) |
| 15.25 -15.50 | Round table discussion with all speakers |
| 15.50-16.00 | Voting for next year’s topics and Wrap up – Steve Humphries (UK) |
| 16.00-17.00 | Networking drinks |
Date : 25 mai 2024
Lieu : Lyon